Jasper Bos
Director/Board Member chez ENGENE HOLDINGS INC.
Profil
Jasper Marnix Bos is a Non-Executive Director at enGene Holdings, Inc. and a General Partner at Forbion Capital Partners Management Holding BV.
He previously worked as the Chief Executive Officer at Forbion European Acquisition Corp., Chairman-Supervisory Board at Inthera Bioscience AG, and Director at EpiTherapeutics ApS, Vaximm AG, Galecto Biotech ApS, Prexton Therapeutics SA, ObsEva SA, Calypso Biotech SA, and Neviah Genomics Ltd.
He was also a Managing Director at Merck Ventures BV from 2019 to 2021.
Additionally, he worked as a Manager-Health Economics & Strategy at Netherlands Vaccine Institute.
He holds a doctorate degree from the University of Groningen.
Postes actifs de Jasper Bos
| Sociétés | Poste | Début |
|---|---|---|
| ENGENE HOLDINGS INC. | Director/Board Member | 08/08/2023 |
Forbion Capital Partners Management Holding BV
 Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Private Equity Investor | 01/05/2021 |
Anciens postes connus de Jasper Bos
| Sociétés | Poste | Fin |
|---|---|---|
Merck Ventures BV
 Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Private Equity Investor | 01/05/2021 |
Calypso Biotech SA
 Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Director/Board Member | 01/01/2019 |
Calypso Biotech BV
 Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Director/Board Member | 01/01/2019 |
Prexton Therapeutics SA
 Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Director/Board Member | 01/03/2018 |
Neviah Genomics Ltd.
 Neviah Genomics Ltd. Pharmaceuticals: MajorHealth Technology Neviah Genomics Ltd. develops novel biomarkers for the prediction of drug-induced toxicity. It identifies biomarkers for the prediction of drug-induced toxicity. The firm offers involving cell harvest and culture, compound exposure, mRNA expression analysis and multi-parameter mathematical computation. The company was founded in 2012 and is headquartered in Yavne, Israel. | Director/Board Member | 01/09/2016 |
Formation de Jasper Bos
| University of Groningen | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OBSEVA SA | Health Technology |
| ENGENE HOLDINGS INC. | Health Technology |
| Entreprise privées | 12 |
|---|---|
Forbion Capital Partners Management Holding BV
Forbion Capital Partners Management Holding BV Investment ManagersFinance Forbion Capital Partners Management Holding BV (Forbion) is a Netherlands-based venture capital firm which was founded by Bart Bergstein. Headquartered in Naarden, the firm specializes in late-stage and early-stage clinical development programs to optimize the commercial potential of their investee company's technologies. | Finance |
EpiTherapeutics ApS
 EpiTherapeutics ApS BiotechnologyHealth Technology EpiTherapeutics ApS is a holding company that develops cancer drugs based on research in the field of epigenetics. Its development programs are focused on enzymes involved in the regulation of transcription in cancer - current programs target histone demethylases and methyltransferases. The firm's regulation is commonly used for post-translational covalent modifications of histones and other chromatin-remodeling complexes, which determines whether a gene is accessible and hence, expressed or repressed. Its covalent modifications involved in epigenetic regulation include deoxyribonucleic acid methylation, histone acetylation, and histone methylation. The company was founded by Kristian Helin, Paul Andreas Compare Cloos, Jesper Aagaard Christensen, Karl Agger, and Klaus Hansen on September 18, 2008 and is headquartered in Greve, Denmark. | Health Technology |
Galecto Biotech ApS
 Galecto Biotech ApS Pharmaceuticals: MajorHealth Technology Galecto Biotech ApS provides galectin modulators for the treatment of severe diseases, including fibrosis and cancer. Its products include galectin-3 inhibitors, fibrosis and literature. The company was founded by Tariq Sethi, Hans Thalsgard Schambye, Ulf Jorgen Nilsson, and Hakon Leffler in 2011 and is headquartered in Copenhagen, Denmark. | Health Technology |
Prexton Therapeutics SA
Prexton Therapeutics SA Pharmaceuticals: MajorHealth Technology Prexton Therapeutics SA operates as a biopharmaceutical company which develops novel therapeutic compounds as a new treatment for Parkinson’s disease and other brain disorders. The company was founded by Francois Conquet in 2012 and is headquartered in Geneva, Switzerland. | Health Technology |
Calypso Biotech SA
Calypso Biotech SA Pharmaceuticals: MajorHealth Technology Calypso Biotech SA operates as a innovative biopharmaceutical company for gastrointestinal immunological disorders. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Plan-les-Ouates, Germany. | Health Technology |
Neviah Genomics Ltd.
Neviah Genomics Ltd. Pharmaceuticals: MajorHealth Technology Neviah Genomics Ltd. develops novel biomarkers for the prediction of drug-induced toxicity. It identifies biomarkers for the prediction of drug-induced toxicity. The firm offers involving cell harvest and culture, compound exposure, mRNA expression analysis and multi-parameter mathematical computation. The company was founded in 2012 and is headquartered in Yavne, Israel. | Health Technology |
Inthera Bioscience AG
 Inthera Bioscience AG BiotechnologyHealth Technology Inthera Bioscience AG engages in the research in as well as development, production, and distribution of pharmaceutical, biological, and other products used in the fields of human and veterinary medicine. It also provides related consultancy services. The company was founded by Ulrich Kessler and Paramjit Singh Arora on September 20, 2013 and is headquartered in Zurich, Switzerland. | Health Technology |
Merck Ventures BV
Merck Ventures BV Investment ManagersFinance Merck Ventures BV (Merck Ventures) is a venture capital arm of Merck KGaA founded in 2009. The firm is headquartered in Amsterdam, the Netherlands. | Finance |
Calypso Biotech BV
Calypso Biotech BV BiotechnologyHealth Technology Calypso Biotech BV operates as immunotherapy biotech company. It develops monoclonal antibodies for the treatment of immune pathologies with large unmet medical needs. The company was founded by Alain Vicari and Yolande Chvatchko in 2013 and is headquartered in Amsterdam, the Netherlands. | Health Technology |
Forbion European Acquisition Corp.
 Forbion European Acquisition Corp. Financial ConglomeratesFinance Forbion European Acquisition Corp. is a blank check company. It engages in the business of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was founded by Hugo Alexander Slootweg in 2006 and is headquartered in Wilmington, DE. | Finance |
Vaximm AG
 Vaximm AG Miscellaneous Commercial ServicesCommercial Services Vaximm AG provides active immunotherapies for patients suffering from cancer. It develops and provides vaccines for patients suffering from cancer. The firmalso provides research, development, manufacture, marketing and sale of pharmaceutical products. The company was founded in September 2008 and is headquartered in Basel, Switzerland. | Commercial Services |
| Netherlands Vaccine Institute |
